结构和药理上的洞察力propranolol:一个集成的晶体学视角
Adrianna Witczyńska1, Łukasz Fijałkowski1, Dagmara Mirowska-Guzel2
1Department of Organic Chemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toruń, Poland.
International journal of molecular sciences
|October 29, 2025
概括
这种药物是propranolol.
科学领域:
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
- 药用化学 医学化学
背景情况:
- 普罗巴诺洛尔是一种非选择性的β-上腺素受体抗剂,用于心血管和神经疾病.
- 它的脂性结构促进了中枢神经系统的透,但肝脏代谢限制了生物可用性.
- 了解其分子相互作用是优化其治疗用途的关键.
研究的目的:
- 为了将药理学数据与罗普兰醇的晶体分析相结合.
- 阐明兰醇的受体亲和力和对抗性的分子决定因素.
- 探索兰醇的治疗多功能性和非目标相互作用的结构基础.
主要方法:
- 分析了人类β2-上腺素受体 (hbeta2-AR) 的高分辨率晶体结构 (PDB ID: 6PS5通过SFX).
- 进行了对比结构分析和与其他β-阻断剂 (阿尔普伦诺洛尔,蒂莫洛尔,卡维迪洛尔) 的叠加.
- 药理学分析和对抗选择性行为的评估是整合的.
主要成果:
- 晶体结构揭示了hbeta2-AR亲和力和对抗性的关键结合决定因素.
- 对比分析强调了结构变异如何影响药理动力学和选择性.
- 兰醇的S-反体显示出更高的受体亲和力和强度.
- 确定了与非正规蛋白质 (如细胞酶Cel7A和乳酸铁素) 的非目标相互作用.
结论:
- 兰醇的两性质,立体化学和静电性质塑造了它的药理学特征.
- 结晶学见解支持改进的β-上腺素配体的合理设计.
- 对非标相互作用的进一步研究可能会揭示propanolol的新型治疗应用.
相关概念视频
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.3K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.3K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
Antihypertensive Drugs: Types of β-Blockers
1.4K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.4K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K


